Hand, Foot and Mouth Disease
Conditions
Keywords
EV71 vaccine; Efficacy; Seroprotective correlates
Brief summary
The purpose of this post-marketing study is to evaluate the efficacy, immunogenicity, and safety of the EV71 vaccine post marketing, and explore the protective levels of various enterovirus neutralizing antibodies
Detailed description
This study is a post-marketing aims to evaluate the efficacy, immunogenicity, and safety of the EV71 vaccine, and explore the protective levels of various enterovirus neutralizing antibodies. This study includes the following three sections: (1) efficacy study of EV71 vaccine based on enhanced cases monitoring, using prospective cohort study design (2) study on correlation between EV71 vaccine protection and EV71 antibody levels, using case-control study design (3) pathogenic spectrum and sero-epidemiological investigation of hand, foot and mouth disease (HFMD) in children. 15500 volunteers aged 6-71 months are expected to participate in this study, among which 5000 volunteers aged 6-35 months will receive two doses EV71 vaccine manufactured by Sinovac Biotech Co., Ltd, and constitute the experimental cohort. 10000 unvaccinated volunteers aged 6-35 months will constitute the the control cohort. The efficacy evaluation will be conducted based on the abovementioned two cohort. Enhanced HFMD surveillance system will be established to report the HFMD cases in the abovementioned 2 cohorts, as well as another cohort consisting of 500 volunteers aged 36-71 months. The case surveillance period of this study is one year. Laboratory tests will be conducted for case confirmation.
Interventions
BIOLOGICAL5000 volunteers (6-35 months)-EV71 vaccine
two doses EV71 vaccines will be administrated on day 0, 30 respectively
Sponsors
Sinovac Biotech Co., Ltd
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Months to 71 Months
Healthy volunteers
Yes
Inclusion criteria
* Volunteers aged 6-71 months; * Guardians of the participants voluntarily to vaccinate the participants with EV71 vaccine at their own expense; * Guardians of the participants should be capable of understanding the written consent form, and such form should be signed prior to enrollment; * Complying with the requirement of the study protocol;
Exclusion criteria
* History of HFMD prior to the study entry; * Prior vaccination with EV71 vaccine; * History of allergy to any vaccine, or any ingredient, excipients and Gentamycin Sulfate of the vaccine, or serious adverse reaction(s) to vaccination, such as urticaria, dyspnea, angioneurotic edema, abdominal pain, etc. (only for 6-35 months old subjects of the vaccinated group) ; * Congenital malformation, developmental disorders, genetic defects, or severe malnutrition (only for 6-35 months old subjects of the vaccinated group); * Severe/uncontrollable nervous system disease (epilepsy, seizures or convulsions) or mental illness (only for 6-35 months old subjects of the vaccinated group); * Autoimmune disease or immunodeficiency/immunosuppressive (only for 6-35 months old subjects of the vaccinated group) ; * History of asthma, angioedema, diabetes or malignancy (only for 6-35 months old subjects of the vaccinated group); * Acute disease or acute stage of chronic disease within 7 days prior to study entry (only for 6-35 months old subjects of the vaccinated group); * Axillary temperature \> 37.0 Celsius (only for 6-35 months old subjects of the vaccinated group)； * Any other factor that suggesting the volunteer is unsuitable for this study based on the opinions of investigators.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The efficacy of two doses EV71 vaccine in the 6-35 months old subjects | During the case monitoring period of 1 year | Vaccine Efficacy (VE)=(incidence difference between vaccinated and unvaccinated group/incidence of vaccinated group)\*100% |
| The seroprotective titers of the EV71 neutralizing antibody in the 6-35 months old subjects | Through study completion, an average of 1 year | Immune correlates of protection |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The seropositive rate of the EV71, CA16, CA6, CA10 neutralizing antibody in the 6-71 months old subjects | During the study period, 2 months after the study beginning | Serum epidemiological index |
| The geometric mean titer (GMT) of the EV71, CA16, CA6, CA10 neutralizing antibody in the 6-71 months old subjects | During the study period, 2 months after the study beginning | Serum epidemiological index |
| The incidence of adverse events after the EV71 vaccination in the 6-35 months old subjects | Within 6 months after each dose injection | Safety index |
| The geometric mean increase (GMI) of the EV71 neutralizing antibody after vaccination in the 6-35 months old subjects | 30 days after two doses | Immunogenicity index |
| Proportions of various pathogens in the confirmed HFMD cases | Through study completion, an average of 1 year | Pathogen spectrum index |
| The seroconversion rate of the EV71 neutralizing antibody after vaccination in the 6-35 months old subjects | 30 days after two doses | Immunogenicity index |
| The seroprotective titers of the CA16, CA6, CA10 neutralizing antibody in the 6-35 months old subjects | Through study completion, an average of 1 year | Immune correlates of protection |
Countries
China
Outcome results
None listed